- Home
- ICON vs REVB Comparison
ICON vs REVB Comparison
Compare ICON & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- REVB
- Stock Information
- Founded
- ICON 2023
- REVB 2020
- Country
- ICON Greece
- REVB United States
- Employees
- ICON N/A
- REVB N/A
- Industry
- ICON
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- ICON
- REVB Health Care
- Exchange
- ICON Nasdaq
- REVB Nasdaq
- Market Cap
- ICON 4.7M
- REVB 4.4M
- IPO Year
- ICON 2024
- REVB N/A
- Fundamental
- Price
- ICON $2.11
- REVB $1.92
- Analyst Decision
- ICON Strong Buy
- REVB
- Analyst Count
- ICON 1
- REVB 0
- Target Price
- ICON $4.50
- REVB N/A
- AVG Volume (30 Days)
- ICON 33.9K
- REVB 834.9K
- Earning Date
- ICON 09-10-2025
- REVB 11-07-2025
- Dividend Yield
- ICON 100.00%
- REVB N/A
- EPS Growth
- ICON N/A
- REVB N/A
- EPS
- ICON N/A
- REVB N/A
- Revenue
- ICON $6,137,000.00
- REVB N/A
- Revenue This Year
- ICON $94.05
- REVB N/A
- Revenue Next Year
- ICON $18.81
- REVB N/A
- P/E Ratio
- ICON N/A
- REVB N/A
- Revenue Growth
- ICON 25.60
- REVB N/A
- 52 Week Low
- ICON $1.60
- REVB $1.90
- 52 Week High
- ICON $130.80
- REVB $60.48
- Technical
- Relative Strength Index (RSI)
- ICON 46.72
- REVB 30.94
- Support Level
- ICON $1.87
- REVB $2.20
- Resistance Level
- ICON $2.18
- REVB $2.90
- Average True Range (ATR)
- ICON 0.11
- REVB 0.21
- MACD
- ICON 0.02
- REVB -0.08
- Stochastic Oscillator
- ICON 57.83
- REVB 2.00
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).